Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 12:22 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for the company's fundamentals and stock price.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 12:17 AM UTC

Segments 12-15 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, the first large late-stage study of a custom cancer therapy using mRNA technology. Patients receiving the treatment with Keytruda went longer without cancer recurrence than those on Keytruda alone, and Moderna shares closed 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 12:12 AM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, showing longer progression-free survival compared to Keytruda alone. This is a material positive catalyst for Moderna, supporting a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 12:07 AM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom treatment plus Keytruda showing longer progression-free survival than Keytruda alone, leading to a 177% stock surge. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 12:02 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, causing a 177% stock surge. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:57 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:52 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for the company, supporting a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:47 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, causing a 177% stock surge. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:42 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a material positive catalyst that led to a 177% stock surge. This supports a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:37 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. This is a material positive catalyst for Moderna, supporting a BUY operation.